Chugai Pharmaceutical Co., Ltd.
4519
Clasificación en acciones
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Precio por acción
$41.60
Capitalización bursátil
$68.46B
Cambio (1 día)
0.94%
Cambio (1 año)
-12.56%
País
JP
Comercio Chugai Pharmaceutical Co., Ltd. (4519)
Categoría
Healthcare
Ganancias de Chugai Pharmaceutical Co., Ltd. (4519)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Chugai Pharmaceutical Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Chugai Pharmaceutical Co., Ltd. desde 2003 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2025 | $3.81B | 10.18% |
| 2024 | $3.46B | 9.91% |
| 2023 | $3.15B | -22.32% |
| 2022 | $4.05B | 11.19% |
| 2021 | $3.64B | 26.14% |
| 2020 | $2.89B | 51.00% |
| 2019 | $1.91B | 72.67% |
| 2018 | $1.11B | 28.63% |
| 2017 | $861.20M | 35.29% |
| 2016 | $636.58M | -12.20% |
| 2015 | $725.04M | 14.00% |
| 2014 | $635.98M | -12.96% |
| 2013 | $730.71M | -13.05% |
| 2012 | $840.36M | 13.52% |
| 2011 | $740.25M | -8.49% |
| 2010 | $808.92M | -16.02% |
| 2009 | $963.18M | 38.51% |
| 2008 | $695.38M | 17.04% |
| 2007 | $594.11M | 12.26% |
| 2006 | $529.22M | -27.64% |
| 2005 | $731.36M | 30.51% |
| 2004 | $560.37M | 21.93% |
| 2003 | $459.59M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
